Dr. Martens Logo
GB00BL6NGV24
A2QNAR
DOCMF

Dr. Martens

Kurser indlæses...

Prognose

Køb
  0
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Dr. Martens misses Q2 earnings forecast, margins improve thanks to pricing strategy

    Dr. Martens reported EPS of 4.23p for the second half of 2026, missing analysts' estimate of 4.84p; revenue of £442.95m was slightly below expectations. At the same time, adjusted profit before tax rose 61% and the gross margin improved due to a strategic focus on full‑price sales. The stock rose 1.04% after the results, and management provided an outlook with EPS forecasts of $1.52 (2027) and $1.68 (2028). » Mere på de.investing.com


  • Dr. Martens sacrifices revenue to return to profitability

    Dr. Martens reported a 3.1% decline in revenue to £251 million for the third quarter of 2025/26 after offering fewer discounts. Weaker consumer demand in Europe and US tariffs are weighing on the business; in response, Dr. Martens is raising prices in the US and shifting production from Laos to Vietnam. For the full year, largely flat revenues are expected, while the stock has fallen by more than 10% after the lackluster outlook. The company also plans a broader product range with more shoes, sandals and bags to make growth profitable again. » Mere på manager-magazin.de


  • Dr. Martens share falls after Q3 earnings call despite strategic realignment

    Dr. Martens announced a multi‑year realignment aimed at higher revenue quality and a material increase in profit before tax. Despite positive signs — including regional wholesale growth for the first time in more than three years — the share fell 8.13% after the call as e‑commerce revenues were pressured by reduced promotions. Management plans price increases in the US, expansion of new product families and a cross‑channel customer focus, but sees risks from US consumer patterns and challenging EMEA conditions. » Mere på de.investing.com


  • Dr. Martens confirms 2026 guidance despite hit from US tariffs

    Dr. Martens reports H1 2026 revenue of £322m and a gross margin of 65.2%, beating expectations, with an adjusted pre-tax loss of £9.4m. The company proposes a dividend of 85p and maintains its full-year guidance of £53–60m (excluding US tariffs), but expects a “high single‑digit millions of pounds” impact from tariffs, about half of which should be offset in 2026 and full offset expected from 2027. Inventory fell 19% to £200m and net debt was £302m; regionally, the Americas showed strength, EMEA weakness, and APAC good performance. » Mere på de.investing.com

I 2026 har Dr. Martens allerede udloddet 0,0299 € i udbytte. Den seneste udlodning fandt sted i oktober.

Virksomhedstal

I det seneste kvartal havde Dr. Martens en omsætning på 508,01 mio. € og et nettoresultat på 38,77 mio. €
(EUR) marts 2026
YoY
Omsætning 508,01 mio. -
Bruttofortjeneste 300,06 mio. -
Nettoresultat 38,77 mio. -
EBITDA 123,19 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
733,87 mio. €
Antal aktier
957,26 mio.
Højeste/laveste i 52 uger
1,09 € - 0,73 €
Udbytteafkast
3,82 %
Udbytte TTM
0,0298 €
Beta
0,26
P/E (PE Ratio)
21,33
PEG (PEG Ratio)
0,04
K/I (PB Ratio)
1,41
P/S (PS Ratio)
0,66

Virksomhedsprofil

Dr. Martens plc designer, udvikler, indkøber, markedsfører, sælger og distribuerer fodtøj i Europa, Mellemøsten, Afrika, Amerika og Asien-Stillehavsregionen. Virksomhedens produktsegmenter omfatter originals, fusion, kids og casual samt tilbehør. Virksomheden tilbyder sine produkter under varemærket Dr. Martens. Dr. Martens plc blev grundlagt i 1945 og har hovedkontor i London, Storbritannien.

Navn
Dr. Martens
CEO
Ije Nwokorie
Hjemsted London, gl
Storbritannien
Websted
Sektor
Cykliske forbrugsvarer
Branche
Tekstiler, beklædning og luksusvarer
Børsnotering
29.01.2021
Medarbejdere 2.377

Tickersymboler

Børs Symbol
Pnk
DOCMF
London Stock Exchange
DOCS.L
Frankfurt
3U2.F
Düsseldorf
3U2.DU
London
DOCS.L
München
3U2.MU
🍪

Parqet  bruger cookies. Læs mere